We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Group to Develop Blood Test for Breast Cancer

By HospiMedica staff writers
Posted on 13 Oct 2005
A consortium of internationally recognized scientists at seven leading biomedical-research centers has announced its quest to pinpoint breast-cancer biomarkers, unique proteins in the blood that may signal the presence of cancer at its earliest stages, when survival rates are highest.

The consortium, called the Breast Cancer Biomarker Discovery Project, brings together U.S. More...
researchers in the field of proteomics, informatics, and clinical breast-cancer care to share research methodologies, critical data, and tissue and blood samples from human subjects to speed the discovery of biomarkers that may lead to a blood test for early breast-cancer detection. The leader of the consortium is Lee Hartwell, Ph.D., Nobel laureate and president and director of Fred Hutchinson Cancer Research Center (Seattle, WA, USA; www.fhcrc.org). Member scientists come from Fred Hutchinson Cancer Research Center and six other prominent U.S. cancer research centers.

The group's effort is being funded by a three-year, U.S.$9 million award from the Entertainment Industry Foundation (EIF, Los Angeles, CA, USA) and its Women's Cancer Research Fund (WCRF). EIF is the philanthropic arm of the entertainment industry. "By creating this consortium, EIF aims to fast-track the development of blood tests for screening purposes, which in turn could help dramatically improve cancer-survival rates,” said Kate Capshaw, honorary co-chair.

The five-year survival rate for breast-cancer patients with early stage disease is 85-95%, but the survival rate is only 22% in patients whose cancer has spread to distant organs. The researchers will work to isolate the proteins that herald early-stage breast cancer when detected in serum. Led by Dr. Hartwell, Hutchinson Center researchers will provide expertise in the areas of whole-protein analysis, bioinformatics, proteomics-technology assessment, marker discovery, and antibody technology.




Related Links:
Entertainment Industry Foundation

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.